Curcumin, inflammation, and chronic diseases: How are they linked?

Molecules

Volumn 20, Issue 5, 2015, Pages 9183-9213

  He, Yan ^a   Yue, Yuan ^a   Zheng, Xi ^a,b   Zhang, Kun ^a   Chen, Shaohua ^c   Du, Zhiyun ^a  

^a GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^b RUTGERS UNIVERSITY   (United States)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Antioxidant; Chronic diseases; Curcumin; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CURCUMIN;

CHEMISTRY; CHINESE MEDICINE; CHRONIC DISEASE; DRUG EFFECTS; HUMAN; INFLAMMATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHRONIC DISEASE; CURCUMIN; HUMANS; INFLAMMATION; MEDICINE, CHINESE TRADITIONAL; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84934333177     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20059183     Document Type: Review

References (205)

1. Lestari, M.L.; Indrayanto, G. Curcumin. Profiles Drug Subst. Excip. Relat. Methodol. 2014, 39, 113-204.
2. Gupta, S.C.; Patchva, S.; Koh, W.; Aggarwal, B.B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol. 2012, 39, 283-299.
3. Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa, a review of preclinical and clinical research. Altern. Med. Rev. 2009, 14, 141-153.
4. Koeberle, A.; Werz, O. Multi-Target approach for natural products in inflammation. Drug Discov. Today 2014, 19, 1871-1882.
5. Allison, D.J.; Ditor, D.S. Immune dysfunction and chronic inflammation following spinal cord injury. Spinal Cord 2014, 53, 14-18.
6. Schraufstatter, I.; Hyslop, P.A.; Jackson, J.H.; Cochrane, C.G. Oxidant-induced DNA damage of target cell. J. Clin. Investig. 1988, 82, 1040-1050.
7. Sikora, E.; Scapagnini, G.; Barbagallo, M. Curcumin, inflammation, ageing and age-related diseases. Immun. Ageing 2010, 7, 1-4.
8. Naksuriya, O.; Okonogi, S.; Schiffelers, R.M.; Hennink, W.E. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 2014, 35, 3365-3383.
9. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer, How are they linked? Free Radic. Biol. Med. 2010, 49, 1603-1616.
10. Durackova, Z. Some current insights into oxidative stress. Physiol. Res. 2010, 59, 459-469.
11. Ishibashi, T. Molecular hydrogen, new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases. Curr. Pharm. Des. 2013, 19, 6375-6381.
12. Debnath, T.; Kim da, H.; Lim, B.O. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules 2013, 18, 7253-7270.
13. Beal, M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15, S189-S194.
14. Tapia, E.; Zatarain-Barrón, Z.L.; Hernández-Pando, R.; Zarco-Márquez, G.; Molina-Jijón, E.; Cristóbal-García, M.; Santamaría, J.; Pedraza-Chaverri, J. Curcumin reverses glomerular hemodynamic alterations and oxidant stress in 5/6 nephrectomized rats. Phytomedicine 2013, 20, 359-366.
15. Correa, F.; Buelna-Chontal, M.; Hernández-Reséndiz, S.; García-Niño, W.R.; Roldán, F.J.; Soto, V.; Silva-Palacios, A.; Amador, A.; Pedraza-Chaverrí, J.; Tapia, E.; et al. Curcumin maintains cardiac and mitochondrial function in chronic kidney disease. Free Radic. Biol. Med. 2013, 61, 119-129.
16. Carmona-Ramírez, I.; Santamaría, A.; Tobón-Velasco, J.C.; Orozco-Ibarra, M.; Maldonado, P.D.; González-Herrera, I.G.; Pedraza-Chaverrí, J. Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity. J. Nutr. Biochem. 2013, 24, 14-24.
17. González-Reyes, S.; Guzmán-Beltrán, S.; Medina-Campos, O.N.; Pedraza-Chaverri, J. Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxid. Med. Cell. Longev. 2013, 2013, 801418.
18. Cordero, H.I.; Martín, M.A.; Goya, L.; Ramos, S. Cocoa flavonoids protect hepatic cells against high-glucose-induced oxidative stress: Relevance of MAPKs. Mol. Nutr. Food Res. 2015, 59, 597-609.
19. Lin, M.; Zhai, X.; Wang, G.; Tian, X.; Gao, D.; Shi, L.; Wu, H.; Fan, Q.; Peng, J.; Liu, K.; et al. Salvianolic acid B protects against acetaminophen hepatotoxicity by inducing Nrf2 and phase II detoxification gene expression via activation of the PI3K and PKC signaling pathways. J. Pharmacol. Sci. 2015, 127, 203-210.
20. Dey, A.; Lakshmanan, J. The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. Food Funct. 2013, 4, 1148-1184.
21. Malhotra, A.; Nair, P.; Dhawan, D.K. Premature Mitochondrial Senescence and Related Ultrastructural Changes during Lung Carcinogenesis Modulation by Curcumin and Resveratrol. Ultrastruct. Pathol. 2012, 36, 179-184.
22. Chang, N.S.; Joki, N.; Mattison, J.; Dinh, T.; John, S. Characterization of serum adhesive proteins that block tumor necrosis factor-mediated cell death. Cell Death Differ. 1997, 4, 779-786.
23. Anthwal, A.; Thakur, B.K.; Rawat, M.S.; Rawat, D.S.; Tyagi, A.K.; Aggarwal, B.B. Synthesis, characterization and in vitro anticancer activity of C-5 curcumin analogues with potential to inhibit TNF-α-induced NF-κB activation. Biomed Res. Int. 2014, 2014, 524161.
24. Gupta, S.C.; Tyagi, A.K.; Deshmukh-Taskar, P.; Hinojosa, M.; Prasad, S.; Aggarwal, B.B. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch. Biochem. Biophys. 2014, 559, 91-99.
25. Giordano, S.; Darley, U.V.; Zhang, J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol. 2013, 2, 82-90.
26. Sun, Y.M.; Zhang, H.Y.; Chen, D.Z.; Liu, C.B. Theoretical elucidation on the antioxidant mechanism of curcumin, A DFT study. Org. Lett. 2002, 4, 2909-2911.
27. Priyadarsini, K.I.; Maity, D.K.; Naik, G.H.; Kumar, M.S.; Unnikrishnan, M.K.; Satav, J.G.; Mohan, H. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic. Biol. Med. 2003, 35, 475-484.
28. Atreya, I.; Atreya, R.; Neurath, M.F. NF-kappaB in inflammatory bowel disease. J. Intern. Med. 2008, 263, 591-596.
29. Taylor, R.A.; Leonard, M.C. Curcumin for inflammatory bowel disease, a review of human studies. Altern. Med. Rev. 2011, 16, 152-156.
30. Baliga, M.S.; Joseph, N.; Venkataranganna, M.V.; Saxena, A.; Ponemone, V.; Fayad, R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis, preclinical and clinical observations. Food Funct. 2012, 3, 1109-1117.
31. Hanai, H.; Iida, T.; Takeuchi, K.; Watanabe, F.; Maruyama, Y.; Andoh, A.; Tsujikawa, T.; Fujiyama, Y.; Mitsuyama, K.; Sata, M.; et al. Curcumin maintenance therapy for ulcerative colitis, randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 2006, 4, 1502-1506.
32. Sugimoto, K.; Hanai, H.; Tozawa, K.; Aoshi, T.; Uchijima, M.; Nagata, T.; Koide, Y. Curcumin prevents and ameliorates trinitrobenzene surfonic acide induced colitis in mice. Gastroenterology 2002, 123, 1912-1922.
33. McCann, M.J.; Johnston, S.; Reilly, K.; Men, X.; Burgess, E.J.; Perry, N.B.; Roy, N.C. The Effect of Turmeric (Curcuma longa) Extract on the Functionality of the Solute Carrier Protein 22 A4 (SLC22A4) and Interleukin-10 (IL-10) Variants Associated with Inflammatory Bowel Disease. Nutrients 2014, 6, 4178-4190.
34. Beloqui, A.; Coco, R.; Memvanga, P.B.; Ucakar, B.; des Rieux, A.; Préat, V. pH-Sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int. J. Pharm. 2014, 473, 203-212.
35. Aggarwal, B.B.; Gupta, S.C.; Sung, B. Curcumin, an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br. J. Pharmacol. 2013, 169, 1672-1692.
36. Topcu-Tarladacalisir, Y.; Akpolat, M.; Uz, Y.H.; Kizilay, G.; Sapmaz-Metin, M.; Omurlu, I.K.; Cerkezkayabekir, A. Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis, the roles of c-Jun N-Terminal kinase and p38 mitogen-Activated protein kinase. J. Med. Food 2013, 16, 296-305.
37. Larmonier, C.B.; Midura-Kiela, M.T.; Ramalingam, R.; Laubitz, D.; Janikashvili, N.; Larmonier, N.; Ghishan, F.K.; Kiela, P.R. Modulation of neutrophil motility by curcumin, implications for inflammatory bowel disease. Inflamm. Bowel. Dis. 2011, 17, 503-515.
38. Epstein, J.; Docena, G.; MacDonald, T.T.; Sanderson, I.R. Curcumin suppresses p38 mitogen-Activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br. J. Nutr. 2010, 103, 824-832.
39. Binion, D.G.; Otterson, M.F.; Rafiee, P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008, 57, 1509-1517.
40. Binion, D.G.; Heidemann, J.; Li, M.S.; Nelson, V.M.; Otterson, M.F.; Rafiee, P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB, inhibitory role of curcumin. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297, G259-G268.
41. Epstein, J.; Sanderson, I.R.; Macdonald, T.T. Curcumin as a therapeutic agent: The evidence from in vitro, animal and human studies. Br. J. Nutr. 2010, 103, 1545-1557.
42. Hanai, H.; Sugimoto, K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr. Pharm. Des. 2009, 15, 2087-2094.
43. Motawi, T.K.; Rizk, S.M.; Shehata, A.H. Effects of curcumin and Ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease. J. Physiol. Biochem. 2012, 68, 529-539.
44. Talukdar, R.; Tandon, R.K. Pancreatic stellate cells: New target in the treatment of chronic pancreatitis. J. Gastroenterol. Hepatol. 2008, 23, 34-41.
45. Bhardwaj, P.; Yadav, R.K. Chronic pancreatitis, role of oxidative stress and antioxidants. Free Radic. Res. 2013, 47, 941-949.
46. Ahmed Ali, U.; Jens, S.; Busch, O.R.; Keus, F.; van Goor, H.; Gooszen, H.G.; Boermeester, M.A. Antioxidants for pain in chronic pancreatitis. Cochrane Database Syst. Rev. 2014, 8, CD008945.
47. Siriwardena, A.K. Reappraisal of xenobiotic-induced, oxidative stress-mediated cellular injury in chronic pancreatitis: A systematic review. World J. Gastroenterol. 2014, 20, 3033-3043.
48. Masamune, A. Genetics of Pancreatitis: The 2014 Update. Tohoku J. Exp. Med. 2014, 232, 69-77.
49. Lévy, P.; Domínguez-Muñoz, E.; Imrie, C.; Löhr, M.; Maisonneuve, P. Epidemiology of chronic pancreatitis, burden of the disease and consequences. United Eur. Gastroenterol. J. 2014, 2, 345-354.
50. Lazutkin, M.V. Percutaneous puncture and endoscopic interventions in treatment of complicated chronic pancreatitis. Vestn. Khir. Im. I I Grek. 2014, 173, 118-121.
51. Shishodia, S. Molecular mechanisms of curcumin action, gene expression. Biofactors 2013, 39, 37-55.
52. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin, preclinical and clinical studies. Anticancer Res. 2003, 23, 363-398.
53. Gulcubuk, A.; Haktanir, D.; Cakiris, A.; Ustek, D.; Guzel, O.; Erturk, M.; Karabagli, M.; Akyazi, I.; Cicekci, H.; Altunatmaz, K.; et al. Effects of curcumin on proinflammatory cytokines and tissue injury in the early and late phases of experimental acute pancreatitis. Pancreatology 2013, 13, 347-354.
54. Nagar, A.B.; Gorelick, F.S. Acute pancreatitis. Curr. Opin. Gastroenterol. 2004, 20, 439-443.
55. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14, 4491-4499.
56. Durgaprasad, S.; Pai, C.G.; Vasanthkumar; Alvres, J.F.; Namitha, S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J. Med. Res. 2005, 122, 315-318.
57. Dorsey, E.R.; George, B.P.; Leff, B.; Willis, A.W. The coming crisis, obtaining care for the growing burden of neurodegenerative conditions. Neurology 2013, 80, 1989-1996.
58. Lee, J.; Giordano, S.; Zhang, J. Autophagy, mitochondria and oxidative stress, cross-Talk and redox signalling. Biochem. J. 2012, 441, 523-540.
59. Höhn, A.; Grune, T. Lipofuscin, formation, effects and role of macroautophagy. Redox Biol. 2013, 1, 140-144.
60. Zhang, J. Autophagy and mitophagy in cellular damage control. Redox Biol. 2013, 1, 19-23.
61. Kim, D.S.; Kim, J.Y.; Han, Y. Curcuminoids in neurodegenerative diseases. Recent Pat. CNS Drug Discov. 2012, 7, 184-204.
62. Banji, O.J.; Banji, D.; Ch, K. Curcumin and hesperidin improve cognition by suppressing mitochondrial dysfunction and apoptosis induced by D-galactose in rat brain. Food Chem. Toxicol. 2014, 74, 51-59.
63. Eckert, G.P.; Renner, K.; Eckert, S.H.; Eckmann, J.; Hagl, S.; Abdel-Kader, R.M.; Kurz, C.; Leuner, K.; Muller, W.E. Mitochondrial dysfunction-A pharmacological target in Alzheimer's disease. Mol. Neurobiol. 2012, 46, 136-150.
64. Monroy, A.; Lithgow, G.J.; Alavez, S. Curcumin and neurodegenerative diseases. Biofactors 2013, 39, 122-132.
65. Hamaguchi, T.; Ono, K.; Yamada, M. Review: Curcumin and Alzheimer's disease. CNS Neurosci. Ther. 2010, 16, 285-297.
66. Libby, P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006, 83, 456S-460S.
67. Wongcharoen, W.; Phrommintikul, A. The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 2009, 133, 145-151.
68. Chen, T.H.; Yang, Y.C.; Wang, J.C.; Wang, J.J. Curcumin treatment protects against renal ischemia and reperfusion injury-induced cardiac dysfunction and myocardial injury. Transplant. Proc. 2013, 45, 3546-3549.
69. Ahuja, S.; Kohli, S.; Krishnan, S.; Dogra, D.; Sharma, D.; Rani, V. Curcumin, a potential therapeutic polyphenol, prevents noradrenaline-induced hypertrophy in rat cardiac myocytes. J. Pharm. Pharmacol. 2011, 63, 1604-1612.
70. Bronte, E.; Coppola, G.; di Miceli, R.; Sucato, V.; Russo, A.; Novo, S. Role of curcumin in idiopathic pulmonary arterial hypertension treatment, a new therapeutic possibility. Med. Hypotheses 2013, 81, 923-926.
71. Meng, Z.; Yan, C.; Deng, Q.; Gao, D.F.; Niu, X.L. Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-κB pathways. Acta Pharmacol. Sin. 2013, 34, 901-911.
72. Kapakos, G.; Youreva, V.; Srivastava, A.K. Cardiovascular protection by curcumin, molecular aspects. Indian J. Biochem. Biophys. 2012, 49, 306-315.
73. Parodi, F.E.; Mao, D.; Ennis, T.L.; Pagano, M.B.; Thompson, R.W. Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann. Vasc. Surg. 2006, 20, 360-368.
74. Zingg, J.M.; Hasan, S.T.; Meydani, M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 2013, 39, 101-121.
75. Duan, W.; Yang, Y.; Yan, J.; Yu, S.; Liu, J.; Zhou, J.; Zhang, J.; Jin, Z.; Yi, D. The effects of curcumin post-Treatment against myocardial ischemia and reperfusion by activation of the JAK2/STAT3 signaling pathway. Basic Res. Cardiol. 2012, 107, 263.
76. Bugyei-Twum, A.; Advani, A.; Advani, S.L.; Zhang, Y.; Thai, K.; Kelly, D.J.; Connelly, K.A. High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc. Diabetol. 2014, 13, 89.
77. Song, Y.; Ge, W.; Cai, H.; Zhang, H. Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting the phosphatidylinositol 3 kinase/Akt/nuclear factor-κB pathway. J. Cardiovasc. Pharmacol. Ther. 2013, 18, 560-569.
78. Zikaki, K.; Aggeli, I.K.; Gaitanaki, C.; Beis, I. Curcumin induces the apoptotic intrinsic pathway via upregulation of ROS and JNKs in H9c2 cardiac myoblasts. Apoptosis 2014, 19, 958-974.
79. Locksley, R.M. Asthma and allergic inflammation. Cell 2010, 140, 777-783.
80. Redwan, M.; Solomon, O.O. Allergy, asthma, and inflammation, which inflammatory cell type is more important? Allergy Asthma Clin. Immunol. 2008, 4, 150-156.
81. Kurup, V.P.; Barrios, C.S. Immunomodulatory effects of curcumin in allergy. Mol. Nutr. Food Res. 2008, 52, 1031-1039.
82. Nilani, P.; Kasthuribai, N.; Duraisamy, B.; Dhamodaran, P.; Ravichandran, S.; Ilango, K.; Suresh, B. Invitro antioxidant activity of selected antiasthmatic herbal constituents. Anc. Sci. Life 2009, 28, 3-6.
83. Rennolds, J.; Malireddy, S.; Tridandapani, S.; Parinandi, N.; Boyaka, P.N.; Cormet-Boyaka, E.; Hassan, F. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. Biochem. Biophys. Res. Commun. 2012, 417, 256-261.
84. Ammar, S.M.; Gameil, N.M.; Shawky, N.M.; Nader, M.A. Comparative evaluation of anti-inflammatory properties of thymoquinone and curcumin using an asthmatic murine model. Int Immunopharmacol. 2011, 11, 2232-2236.
85. Chong, L.; Zhang, W.; Nie, Y.; Yu, G.; Liu, L.; Lin, L.; Wen, S.; Zhu, L.; Li, C. Protective effect of curcumin on acute airway inflammation of allergic asthma in mice through Notch1-GATA3 signaling pathway. Inflammation 2014, 37, 1476-1485.
86. Thakare, V.N.; Osama, M.M.; Naik, S.R. Therapeutic potential of curcumin in experimentally induced allergic rhinitis in guinea pigs. Int. Immunopharmacol. 2013, 17, 18-25.
87. Ma, C.; Ma, Z.; Fu, Q.; Ma, S. Curcumin attenuates allergic airway inflammation by regulation of CD4+CD25+ regulatory T cells (Tregs)/Th17 balance in ovalbumin-sensitized mice. Fitoterapia 2013, 87, 57-64.
88. Chung, S.H.; Choi, S.H.; Choi, J.A.; Chuck, R.S.; Joo, C.K. Curcumin suppresses ovalbumin-induced allergic conjunctivitis. Mol. Vis. 2012, 18, 1966-1972.
89. Obata, K.; Kojima, T.; Masaki, T.; Okabayashi, T.; Yokota, S.; Hirakawa, S.; Nomura, K.; Takasawa, A.; Murata, M.; Tanaka, S.; et al. Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells. PLoS ONE 2013, 8, e70225.
90. Mahobia, N.; Chaudhary, P.; Kamat, Y. Rothia prosthetic knee joint infection, report and mini-review. New Microbes New Infect. 2013, 1, 2-5.
91. Tyagi, P.; Khan, H.A. Amelioration of oxidative stress in the joint tissue may be the basis for the antiarthritic activity of Terminalia arjuna bark extract. Int. J. Rheum. Dis. 2014, doi:10.1111/1756-185X.
92. Ramadan, G.; El-Menshawy, O. Protective effects of ginger-Turmeric rhizomes mixture on joint inflammation, atherogenesis, kidney dysfunction and other complications in a rat model of human rheumatoid arthritis. Int. J. Rheum. Dis. 2013, 16, 219-229.
93. González-Reimers, E.; Santolaria-Fernández, F.; Martín-González, M.C.; Fernández-Rodríguez, C.M.; Quintero-Platt, G. Alcoholism: A systemic proinflammatory condition. World J. Gastroenterol. 2014, 20, 14660-14671.
94. Godin, A.M.; Araújo, D.P.; Menezes, R.R.; Brito, A.M.; Melo, I.S.; Coura, G.M.; Soares, D.G.; Bastos, L.F.; Amaral, F.A.; Ribeiro, L.S.; et al. Activities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema. Pharmacol. Biochem. Behav. 2014, 122, 291-298.
95. Khraishi, M.M. Experience with subcutaneous abatacept for rheumatoid arthritis, an update for clinicians. Ther. Adv. Musculoskelet. Dis. 2014, 6, 159-168.
96. Lv, Q.; Yin, Y.; Li, X.; Shan, G.; Wu, X.; Liang, D.; Li, Y.; Zhang, X. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis, a meta-Analysis. PLoS ONE 2014, 9, e89442.
97. Banji, D.; Pinnapureddy, J.; Banji, O.J.; Saidulu, A.; Hayath, M.S. Synergistic activity of curcumin with methotrexate in ameliorating Freund's Complete Adjuvant induced arthritis with reduced hepatotoxicity in experimental animals. Eur. J. Pharmacol. 2011, 668, 293-298.
98. Kloesch, B.; Becker, T.; Dietersdorfer, E.; Kiener, H.; Steiner, G. Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes. Int. Immunopharmacol. 2013, 15, 400-405.
99. Shehzad, A.; Rehman, G.; Lee, Y.S. Curcumin in inflammatory diseases. Biofactors 2013, 39, 69-77.
100. Moon, D.O.; Kim, M.O.; Choi, Y.H.; Park, Y.M.; Kim, G.Y. Curcumin attenuates inflammatory response in IL-1 beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int. Immunopharmacol. 2010, 10, 605-610.
101. Lee, K.H.; Abas, F.; Mohamed Alitheen, N.B.; Shaari, K.; Lajis, N.H.; Israf, D.A.; Syahida, A. Chemopreventive effects of a curcumin-like diarylpentanoi[2, 6-bis(2, 5-dimethoxybenzylidene) cyclohexanone] in cellular targets of rheumatoid arthritis in vitro. Int. J. Rheum. Dis. 2014, doi:10.1111/1756-185X.12341.
102. Tsou, H.K.; Chen, H.T.; Chang, C.H.; Yang, W.Y.; Tang, C.H. Apoptosis signal-regulating kinase 1 is mediated in TNF-α-induced CCL2 expression in human synovial fibroblasts. J. Cell. Biochem. 2012, 113, 3509-3519.
103. Yang, C.; Su, X.; Liu, A.; Zhang, L.; Yu, A.; Xi, Y.; Zhai, G. Advances in clinical study of curcumin. Curr. Pharm. Des. 2013, 19, 1966-1973.
104. Ghosh, S.S.; Gehr, T.W.; Ghosh, S. Curcumin and chronic kidney disease (CKD): Major mode of action through stimulating endogenous intestinal alkaline phosphatase. Molecules 2014, 19, 20139-20156.
105. Himmelfarb, J.; Stenvinkel, P.; Ikizler, T.A.; Hakim, R.M. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62, 1524-1538.
106. Moradi, H.; Sica, D.A.; Kalantar-Zadeh, K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am. J. Nephrol. 2013, 38, 136-148.
107. Choi, B.H.; Kang, K.S.; Kwak, M.K. Effect of Redox modulating NRF2 activators on chronic kidney disease. Molecules 2014, 19, 12727-12759.
108. Fujiwara, N.; Nakamura, T.; Sato, E.; Kawagoe, Y.; Hikichi, Y.; Ueda, Y.; Node, K. Renovascular protective effects of erythropoietin in patients with chronic kidney disease. Intern. Med. 2011, 50, 1929-1934.
109. Li, H.; Wang, F.; Zhang, L.; Cao, Y.; Liu, W.; Hao, J.; Liu, Q.; Duan, H. Modulation of NRF2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell Signal. 2011, 23, 1625-1632.
110. Soetikno, V.; Sari, F.R.; Lakshmanan, A.P.; Arumugam, S.; Harima, M.; Suzuki, K.; Kawachi, H.; Watanabe, K. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 Pathway. Mol. Nutr. Food Res. 2013, 57, 1649-1659.
111. Saito, H. Toxico-pharmacological perspective of the NRF2-KEAP1 defense system against oxidative stress in kidney diseases. Biochem. Pharmacol. 2013, 85, 865-872.
112. Kim, H.J.; Sato, T.; Rodriguez-Iturbe, B.; Vaziri, N.D. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J. Pharmacol. Exp. Ther. 2011, 337, 583-590.
113. Zeisberg, M.; Neilson, E.G. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 2010, 21, 1819-1834.
114. Trujillo, J.; Chirino, Y.I.; Molina-Jijón, E.; Andérica-Romero, A.C.; Tapia, E.; Pedraza-Chaverrí, J. Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol. 2013, 1, 448-456.
115. Waly, M.I.; Al Moundhri, M.S.; Ali, B.H. Effect of Curcumin on Cisplatin-And Oxaliplatin-Induced Oxidative Stress in Human Embryonic Kidney (HEK) 293 Cells. Ren. Fail. 2011, 33, 518-523.
116. Gaedeke, J.; Noble, N.A.; Border, W.A. Curcumin blocks multiple sites of the TGF-b signaling cascade in renal cells. Kidney Int. 2004, 66, 112-120.
117. Chiu, J.; Khan, Z.A.; Farhangkhoee, H.; Chakrabarti, S. Curcumin prevents diabetes-Associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-κB. Nutrition 2009, 25, 964-972.
118. Jung, K.A.; Kwak, M.K. The NRF2 system as a potential target for the development of indirect antioxidants. Molecules 2010, 15, 7266-7291.
119. Molina-Jijón, E.; Tapia, E.; Zazueta, C.; el Hafidi, M.; Zatarain-Barrón, Z.L.; Hernández-Pando, R.; Medina-Campos, O.N.; Zarco-Márquez, G.; Torres, I.; Pedraza-Chaverri, J. Curcumin prevents Cr(VI)-induced renal oxidant damage by a mitochondrial pathway. Free Radic. Bio. Med. 2011, 51, 1543-1557.
120. Maradana, M.R.; Thomas, R.; O'Sullivan, B.J. Targeted delivery of curcumin for treating type 2 diabetes. Mol. Nutr. Food Res. 2013, 57, 1550-1556.
121. Meng, B.; Li, J.; Cao, H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr. Pharm. Des. 2013, 19, 2101-2013.
122. Du, Z.Y.; Bao, Y.D.; Liu, Z.; Qiao, W.; Ma, L.; Huang, Z.S.; Gu, L.Q.; Chan, A.S. Curcumin analogs as potent aldose reductase inhibitors. Arch. Pharm. Weinh. 2006, 339, 123-128.
123. Du, Z.Y.; Liu, R.R.; Shao, W.Y.; Mao, X.P.; Ma, L.; Gu, L.Q.; Huang, Z.S.; Chan, A.S. Alpha-glucosidase inhibition of natural curcuminoids and curcumin analogs. Eur. J. Med. Chem. 2006, 41, 213-218.
124. Ramana, K.V.; Srivastava, S.K. Aldose reductase, a novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell Biol. 2010, 42, 17-20.
125. Aldebasi, Y.H.; Aly, S.M.; Rahmani, A.H. Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways. Int. J. Physiol. Pathophysiol. Pharmacol. 2013, 5, 194-202.
126. Zhang, D.W.; Fu, M.; Gao, S.H.; Liu, J.L. Curcumin and diabetes, a systematic review. Evid. Based Complement. Altern. Med. 2013, 16, 1-22.
127. Aggarwal, B.B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 2010, 30, 173-199.
128. Mangge, H.; Summers, K.; Almer, G.; Prassl, R.; Weghuber, D.; Schnedl, W.; Fuchs, D. Antioxidant food supplements and obesity-related inflammation. Curr. Med. Chem. 2013, 20, 2330-2337.
129. Bradford, P.G. Curcumin and obesity. Biofactors 2013, 39, 78-87.
130. Steigerwalt, R.; Nebbioso, M.; Appendino, G.; Belcaro, G.; Ciammaichella, G.; Cornelli, U.; Luzzi, R.; Togni, S.; Dugall, M.; Cesarone, M.R.; et al. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med. 2012, 54, 11-16.
131. Chuengsamarn, S.; Rattanamongkolgul, S.; Phonrat, B.; Tungtrongchitr, R.; Jirawatnotai, S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract, a randomized controlled trial. J. Nutr. Biochem. 2014, 25, 144-150.
132. Prasad, S.; Gupta, S.C.; Tyagi, A.K.; Aggarwal, B.B. Curcumin, a component of golden spice, Frombedside to bench and back. Biotechnol. Adv. 2014, 32, 1053-1064.
133. ClinicalTrial.gov (obesity, curcumin). Available online: http://clinicaltrials.gov/ct2/results?term= +obesity%2C+curcumin&Search=Search (accessed on 25 February 2015).
134. Lambova, S. Cardiac manifestations in systemic sclerosis. World J. Cardiol. 2014, 6, 993-1005.
135. Nguyen, T.A.; Friedman, A.J. Curcumin, a novel treatment for skin-related disorders. J. Drugs Dermatol. 2013, 12, 1131-1137.
136. Zhou, C.F.; Yu, J.F.; Zhang, J.X.; Jiang, T.; Xu, S.H.; Yu, Q.Y.; Zhu, Q.X. N-Acetylcysteine attenuates subcutaneous administration of bleomycin-induced skin fibrosis and oxidative stress in a mouse model of scleroderma. Clin. Exp. Dermatol. 2013, 38, 403-409.
137. Avouac, J.; Borderie, D.; Ekindjian, O.G.; Kahan, A.; Allanore, Y. High DNA oxidative damage in systemic sclerosis. J. Rheumatol. 2010, 37, 2540-2547.
138. Servettaz, A.; Goulvestre, C.; Kavian, N.; Nicco, C.; Guilpain, P.; Chéreau, C.; Vuiblet, V.; Guillevin, L.; Mouthon, L.; Weill, B.; et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol. 2009, 182, 5855-5864.
139. Cappelli, S.; Bellando-Randone, S.; Guiducci, S.; Matucci-Cerinic, M. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatol. Oxf. 2014, 53, 975-987.
140. Gaudet, A.D.; Popovich, P.G. Extracellular matrix regulation of inflammation in the healthy and injured spinal cord. Exp. Neurol. 2014, 258, 24-34.
141. Mukherjee, P.K.; Maity, N.; Nema, N.K.; Sarkar, B.K. Bioactive compounds from nature resources against skin aging. Phytomedicine 2011, 19, 64-73.
142. Hsu, Y.C.; Chen, M.J.; Yu, Y.M.; Ko, S.Y.; Chang, C.C. Suppression of TGF-beta1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids, its potential therapeutic use in the chemoprevention of keloid. Arch. Dermatol. Res. 2010, 302, 717-724.
143. Conboy, L.; Foley, A.G.; O'Boyle, N.M.; Lawlor, M.; Gallagher, H.C.; Murphy, K.J.; Regan, C.M. Curcumin-induced degradation of PKC delta is associated with enhanced dentate NCAM PSA expression and spatial learning in adult and aged Wistar rats. Biochem. Pharmacol. 2009, 77, 1254-1265.
144. Aggarwal, B.B.; Harikumar, K.B. Potential Therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41, 40-59.
145. Song, K.; Peng, S.; Sun, Z.; Li, H.; Yang, R. Curcumin suppresses TGF-beta signaling by inhibition of TGIF degradation in scleroderma fibroblasts. Biochem. Biophys. Res. Commun. 2011, 411, 821-825.
146. Thresiamma, K.C.; George, J.; Kuttan, R. Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Indian J. Exp. Biol. 1996, 34, 845-847.
147. Sobell, J.M.; Leonardi, C.L. Therapeutic development in psoriasis. Semin. Cutan. Med. Surg. 2014, 33, S69-S72.
148. Liu, J.T.; Yeh, H.M.; Liu, S.Y.; Chen, K.T. Psoriatic arthritis, epidemiology, diagnosis, and treatment. World J. Orthop. 2014, 5, 537-543.
149. Haniffa, M.; Gunawan, M.; Jardine, L. Human skin dendritic cells in health and disease. J. Dermatol. Sci. 2015, 77, 85-92.
150. Sinha, A.A. Oxidative stress and autoimmune skin disease. Eur. J. Dermatol. 2013, 23, 5-13.
151. Di, C.A.; Di, M.P.; Nestle, F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Investig. Dermatol. 2009, 129, 1339-1350.
152. Thangapazham, R.L.; Sharad, S.; Maheshwari, R.K. Skin regenerative potentials of curcumin. Biofactors 2013, 39, 141-149.
153. Heng, M.C.; Song, M.K.; Harker, J.; Heng, M.K. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical. Br. J. Dermatol. 2000, 143, 937-949.
154. Jun, S.; Yi, Z.; Hairong, J.; Jinhong, H. Curcumin relieves TPA-induced Th1 inflammation in K14-VEGF transgenic mice. Int. Immunopharmacol. 2015, 25, 235-241.
155. Jun, S.; Yi, Z.; Jinhong, H. Curcumin Inhibits Imiquimod-Induced Psoriasis-Like Inflammation by Inhibiting IL-1beta and IL-6 Production in Mice. PLoS ONE 2013, 8, e67078.
156. Kurd, S.K.; Smith, N.; VanVoorhees, A.; Troxel, A.B.; Badmaev, V.; Seykora, J.T.; Gelfand, J.M. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris, a prospective clinical trial. J. Am. Acad. Dermatol. 2008, 58, 625-631.
157. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
158. Lu, H.; Ouyang, W.; Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4, 221-233.
159. Fan, Y.; Mao, R.; Yang, J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013, 4, 176-185.
160. Grivennikov, S.I.; Karin, M. Dangerous liaisons, STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21, 11-19.
161. Diakos, C.I.; Charles, K.A.; McMillan, D.C.; Clarke, S.J. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014, 15, e493-e503.
162. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883-899.
163. Shehzad, A.; Lee, J.; Lee, Y.S. Curcumin in various cancers. Biofactors 2013, 39, 56-68.
164. Bemis, D.L.; Katz, A.E.; Buttyan, R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin. Investig. Drugs 2006, 15, 1191-1200.
165. ClinicalTrial.gov (curcumin). Available online: http://clinicaltrials.gov/ct2/results?term=curcumin (accessed on 14 February 2015).
166. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin, from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008, 65, 1631-1652.
167. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as 'curecumin', from kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787-809.
168. Frenkel, M.; Abrams, D.I.; Ladas, E.J.; Deng, G.; Hardy, M.; Capodice, J.L.; Winegardner, M.F.; Gubili, J.K.; Yeung, K.S.; Kussmann, H.; et al. Integrating dietary supplements into cancer care. Integr. Cancer Ther. 2013, 12, 369-384.
169. Hutchins-Wolfbrandt, A.; Mistry, A.M. Dietary turmeric potentially reduces the risk of cancer. Asian Pac. J. Cancer Prev. 2011, 12, 3169-3173.
170. Sung, B.; Prasad, S.; Yadav, V.R.; Aggarwal, B.B. Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr. Cancer 2012, 64, 173-197.
171. Aggarwal, B.B.; Vijayalekshmi, R.V.; Sung, B. Targeting inflammatory pathways for prevention and therapy of cancer, short-Term friend, long-Term foe. Clin. Cancer Res. 2009, 15, 425-430.
172. Hasima, N.; Aggarwal, B.B. Cancer-linked targets modulated by curcumin. Int. J. Biochem. Mol. Biol. 2012, 3, 328-351.
173. Datta, R.; Halder, S.K.; Zhang, B. Role of TGF-β signaling in curcumin-mediated inhibition of tumorigenicity of human lung cancer cells. J. Cancer Res. Clin. Oncol. 2013, 139, 563-572.
174. Yang, C.L.; Liu, Y.Y.; Ma, Y.G.; Xue, Y.X.; Liu, D.G.; Ren, Y.; Liu, X.B.; Li, Y.; Li, Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS ONE 2012, 7, e37960.
175. Chen, Q.Y.; Jiao, D.M.; Yao, Q.H.; Yan, J.; Song, J.; Chen, F.Y.; Lu, G.H.; Zhou, J.Y. Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines. Int. J. Oncol. 2012, 40, 1561-1568.
176. Kunnumakkara, A.B.; Diagaradjane, P.; Anand, P.; Harikumar, K.B.; Deorukhkar, A.; Gelovani, J.; Guha, S.; Krishnan, S.; Aggarwal, B.B. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int. J. Cancer 2009, 125, 2187-2197.
177. Tharakan, S.T.; Inamoto, T.; Sung, B.; Aggarwal, B.B.; Kamat, A.M. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem. Pharmacol. 2010, 79, 218-228.
178. Vadhan-Raj, S.; Weber, D.M.; Wang, M.; Giralt, S.A.; Thomas, S.K.; Alexanian, R.; Zhou, X.; Patel, P.; Bueso-Ramos, C.E.; Newman, R.A.; et al. Curcumin downregulates NF-KB and related genes in patients with multiple myeloma, results of a phase I/II study. Blood ASH Annu. Meet. Abstr. 2007, 110, Abstract 1177.
179. Killian, P.H.; Kronski, E.; Michalik, K.M.; Barbieri, O.; Astigiano, S.; Sommerhoff, C.P.; Pfeffer, U.; Nerlich, A.G.; Bachmeier, B.E. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and-2. Carcinogenesis 2012, 33, 2507-2519.
180. Kronski, E.; Fiori, M.E.; Barbieri, O.; Astigiano, S.; Mirisola, V.; Killian, P.H.; Bruno, A.; Pagani, A.; Rovera, F.; Pfeffer, U.; et al. miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancermetastasis via down-regulation of the inflammatory cytokines CXCL1 and-2. Mol. Oncol. 2014, 8, 581-595.
181. Prusty, B.K.; Das, B.C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 2005, 113, 951-960.
182. Shehzad, A.; Wahid, F.; Lee, Y.S. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. Weinh. 2010, 343, 489-499.
183. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm. 2007, 4, 807-818.
184. Sharma, R.A.; Euden, S.A.; Platton, S.L.; Cooke, D.N.; Shafayat, A.; Hewitt, H.R.; Marczylo, T.H.; Morgan, B.; Hemingway, D.; Plummer, S.M.; et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10, 6847-6854.
185. Wahlström, B.; Blennow, G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. Copenh 1978, 43, 86-92.
186. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta. Med. 1998, 64, 353-356.
187. Yang, K.Y.; Lin, L.C.; Tseng, T.Y.; Wang, S.C.; Tsai, T.H. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 853, 183-189.
188. Sun, J.; Bi, C.; Chan, H.M.; Sun, S.; Zhang, Q.; Zheng, Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf. B Biointerfaces 2013, 111, 367-375.
189. Vareed, S.K.; Kakarala, M.; Ruffin, M.T.; Crowell, J.A.; Normolle, D.P.; Djuric, Z.; Brenner, D.E. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomark. Prev. 2008, 17, 1411-1417.
190. Lao, C.D.; Ruffin, M.T., 4th; Normolle, D.; Heath, D.D.; Murray, S.I.; Bailey, J.M.; Boggs, M.E.; Crowell, J.; Rock, C.L.; Brenner, D.E. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 2006, 6, 10.
191. Ringman, J.M.; Frautschy, S.A.; Teng, E.; Begum, A.N.; Bardens, J.; Beigi, M.; Gylys, K.H.; Badmaev, V.; Heath, D.D.; Apostolova, L.G.; et al. Oral curcumin for Alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res. Ther. 2012, 4, 43.
192. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, 2895-2900.
193. Carroll, R.E.; Benya, R.V.; Turgeon, D.K.; Vareed, S.; Neuman, M.; Rodriguez, L.R.; Kakarala, M.; Carpenter, P.M.; Mclaren, C.; Meyskens, F.L.; et al. Phase IIA Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia. Cancer Prev. Res. Phila 2011, 4, 354-364.
194. Kanai, M.; Yoshimura, K.; Asada, M.; Imaizumi, A.; Suzuki, C.; Matsumoto, S.; Nishimura, T.; Mori, Y.; Masui, T.; Kawaguchi, Y.; et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol. 2011, 68, 157-164.
195. Garcea, G.; Berry, D.P.; Jones, D.J.; Singh, R.; Dennison, A.R.; Farmer, P.B.; Sharma, R.A.; Steward, W.P.; Gescher, A.J. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomark. Prev. 2005, 14, 120-125.
196. Lallès, J.P. Intestinal alkaline phosphatase: Novel functions and protective effects. Nutr. Rev. 2014, 72, 82-94.
197. Sehgal, A.; Kumar, M.; Jain, M.; Dhawan, D.K. Combined effects of curcumin and piperine in ameliorating benzo (a) pyrene induced DNA damage. Food Chem. Toxicol. 2011, 49, 3002-3006.
198. Wei, X.C. Synthesis and Antitumor Activity Curcumin Analogs. Ph.D. Thesis, Guangdong University of Technology, Guangzhou, Guangdong, China, 2011.
199. Ghosh, M.; Singh, A.T.; Xu, W.; Sulchek, T.; Gordon, L.I.; Ryan, R.O. Curcumin nanodisks: Formulation and characterization. Nanomedicine 2011, 7, 162-167.
200. Song, L.; Shen, Y.Y.; Hou, J.W.; Lei, L.; Guo, S.R.; Qian, C.Y. Polymeric micelles for parenteral delivery of curcumin: Preparation, characterization and in vitro evaluation. Colloid Surf. A 2011, 390, 25-32.
201. Mulik, R.S.; Mönkkönen, J.; Juvonen, R.O.; Mahadik, K.R.; Paradkar, A.R. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anti-cancer activity by induction of apoptosis. Int. J. Pharm. 2010, 398, 190-203.
202. Bansal, S.S.; Kausar, H.; Vadhanam, M.V.; Ravoori, S.; Gupta, R.C. Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration. Eur. J. Pharm. Biopharm. 2012, 80, 571-577.
203. Moorthi, C.; Kathiresan, K. Curcumin-Piperine/Curcumin-Quercetin/Curcumin-Silibinin dual drug-loaded nanoparticulate combination therapy: A novel approach to target and treat multidrug-resistant cancers. J. Med. Hypotheses Ideas 2013, 7, 15-20.
204. Boruah, B.; Saikia, P.M.; Dutta, R.K. Binding and stabilization of curcumin by mixed chitosan-surfactant systems: A spectroscopic study. J. Photochem. Photobiol. A 2012, 245, 18-27.
205. Kanai, M.; Imaizumi, A.; Otsuka, Y.; Sasaki, H.; Hashiguchi, M.; Tsujiko, K.; Matsumoto, S.; Ishiguro, H.; Chiba, T. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother. Pharmacol. 2012, 69, 65-70.